Abstract:

New uniform response criteria are required to adequately assess clinicaloutcomes in myeloma. The European Group for Blood and Bone MarrowTransplant/International Bone Marrow Transplant Registry criteria have beenexpanded, clarified and updated to provide a new comprehensive evaluationsystem. Categories for stringent complete response and very good partialresponse are added. The serum free light-chain assay is included to allowevaluation of patients with oligo-secretory disease. Inconsistencies in priorcriteria are clarified making confirmation of response and disease progressioneasier to perform. Emphasis is placed upon time to event and duration ofresponse as critical end points. The requirements necessary to use overallsurvival duration as the ultimate end point are discussed. It is anticipatedthat the International Response Criteria for multiple myeloma will be widelyused in future clinical trials of myeloma.

Notes:

Cited By :1292Export Date: 21 February 2017

Website